SUNNYVALE, Calif., Oct. 3, 2023
/PRNewswire/ - Willow Biosciences Inc., ("Willow") (TSX:
WLLW) (OTCQB: CANSF) and SUANFARMA today jointly announced
execution of a collaboration agreement for a cell line productivity
optimization development program for manufacturing a large volume
anti-infective Active Pharmaceutical Ingredient ("API") through
precision fermentation. Through the partnership, SUANFARMA will
have access to Willow's proprietary strain optimization
technologies to develop a more cost-effective production
process.
SUANFARMA has engaged Willow to apply its strain engineering
technology platform to enable more cost-effective commercial
production of the API at SUANFARMA's manufacturing site.
"We are pleased to further expand our successful relationship
with SUANFARMA, to bring sustainably sourced products to market by
leveraging our joint capabilities and their proven efficient
manufacturing resources," said Chris
Savile, Willow's President & CEO. "Together, we see a
number of opportunities to create alternative means to more
sustainably produce key products for better human health and
wellness and we look forward to working with the SUANFARMA
team."
"SUANFARMA CDMO is delighted to further extend our partnership
with Willow toward developing commercial products to broaden our
portfolio by maximizing product quality at reduced cost through
fermentation technology," said Daniel
Rivero, Industrial Director of SUANFARMA. "Following
successful development, we look forward to bringing these
life-enhancing products to market at industrial scale through our
manufacturing site in Europe.
SUANFARMA CDMO provides Contract Development and Manufacturing
Organization services to the market, with solid track record and
expertise in fermentation, purification and chemical synthesis
technologies under the highest standards of quality for the
pharmaceutical and biotech industry."
SUANFARMA CDMO offers a comprehensive approach to Technology
Transfer, aiming to reduce risks and enhance success within their
global project management strategy. Our platform, known as
TT&GO®, employs a systematic and quality-based methodology that
leverages our expertise in GMP manufacturing. This approach ensures
efficient industrialization of processes and thus swift market
commercialization of the final product.
In March 2023, Willow and
SUANFARMA announced an alliance with the intention to work together
on existing pharma and biotechnological capabilities for synthetic
molecules including anti-infectives and other APIs and
intermediates for Pharma and natural ingredients designed for the
Health & Wellness and Food & Beverage industries. Today's
announcement marks further progress in broadening the relationship
by offering an end-to-end synthetic biology solution and expanding
the parties' joint product portfolio.
About WILLOW BIOSCIENCES
Willow develops and produces precision fermented functional
ingredients for the health and wellness, food and beverage and
personal care markets. Willow's FutureGrown™ and BioOxi™ platforms
enable large-scale production with sustainability at its core.
Willow's R&D team has a proven track record of developing and
commercializing bio-based manufacturing processes and products to
benefit our B2B partners and their customers. For more information,
visit www.willowbio.com.
About SUANFARMA
SUANFARMA founded in 1993, is a B2B life science partner
specialized in the development, production, and commercialization
of ingredients for the pharmaceutical, veterinary and nutraceutical
industries.
All facilities comply with the highest existing regulations in
the pharmaceutical industry. With the support of a consolidated and
strong commercial network with 12 local offices placed
strategically around the world, SUANFARMA provides its services to
more than 3,000 active customers in over 70 countries.
SUANFARMA CDMO is a leading provider of CDMO services and
products, and it has an expert team of professionals in charge of
managing the challenge of the complete process for developing,
scaling, and manufacturing small molecule APIs both by fermentation
and by chemical synthesis. We become a trusted innovative partner
providing integrated, real end-to-end solutions and competitive
advantages for our customers to meet their challenges and market
access. This is achieved through two main axes: supply chain and
value chain solutions.
More
information: https://www.suanfarma.com/en/suanfarma-cdmo /
FutureGrown™ and BioOxiTM are registered trademarks
of Willow Biosciences Inc. All other trademarks are trademarks of
their respective holders.
Forward-Looking Statements
This news release may include forward-looking statements
including opinions, assumptions, estimates and the assessment of
future plans and operations of the companies, and, more
particularly, statements concerning: intentions to broaden the
relationship between the two companies by offering an end-to-end
synthetic biology solution and expanding their joint product
portfolio and scaling production; and the business plan of the
companies, generally. When used in this news release, the words
"will," "anticipate," "believe," "estimate," "expect," "intent,"
"may," "project," "should," and similar expressions are intended to
be among the statements that identify forward-looking statements.
The forward-looking statements are founded on the basis of
expectations and assumptions made by the companies which include,
but are not limited to: the success of strategic partnerships; the
ability to obtain and retain applicable licences; the ability to
obtain suitable manufacturing partners and other strategic
relationships; and the successful implementation of the companies'
commercialization and production strategy, generally.
Forward-looking statements are subject to a wide range of risks and
uncertainties, and although the companies believe that the
expectations represented by such forward-looking statements are
reasonable, there can be no assurance that such expectations will
be realized. Any number of important factors could cause actual
results biotechnology industry in general; the success of research
and development strategies; infringement on intellectual property;
failure to benefit from partnerships or successfully integrate
acquisitions; actions and initiatives of federal, state and
provincial governments and changes to government policies and the
execution and impact of these actions, initiatives and policies;
import/export and research restrictions for operations;;
competition from other industry participants; adverse U.S.,
Canadian and global economic conditions; adverse global events and
public-health crises, including the evolving COVID-19 outbreak;
failure to comply with certain regulations; departure of key
management personnel or inability to attract and retain talent; and
other factors more fully described from time to time in the reports
and filings made by Willow with securities regulatory authorities.
Please refer to Willow's most recent annual information form and
management's discussion and analysis for additional risk factors
relating to Willow, which can be accessed either on Willow's
website at www.willowbio.com or under Willow's profile
on www.sedarplus.ca.
The forward-looking statements contained in this news release
are made as of the date hereof and the companies do not undertake
any obligation to update publicly or to revise any of the included
forward-looking statements, except as required by applicable law.
The forward-looking statements contained herein are expressly
qualified by this cautionary statement.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/willow-and-suanfarma-announce-collaboration-on-development-of-large-volume-anti-infective-api-through-precision-fermentation-301944212.html
SOURCE Willow Biosciences Inc.